Brief original article

The effect of the European traditional use directive on the register of herbal medicinal products in Spain


Departamento de Biología de Sistemas, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain

A R T I C L E   I N F O

Article history:
Received 17 October 2014
Accepted 27 January 2015
Available online 30 March 2015

Keywords:
Traditional medicine
Complementary therapies
Herbal Medicine
Legislation and jurisprudence
Dietary Supplements

A B S T R A C T

Background: Directive 2004/24/EC, which came into force in 2011, created new regulatory requirements for traditional herbal medicines (THM). This study compared the Spanish THM registry before and after the Directive came fully into force in 2011.

Methods: We consulted the herbal medicinal plant and drug catalogues (General Council of the Official Colleges of Pharmacists), the website of the European Medicines Agency (EMA), and retail web sites.

Results: Of 315 THM (from 39 companies) licensed in Spain in 2010, only 48 (10 companies) remained licensed in 2013, mainly due to their withdrawal: the EMA had received just 123 applications from Spain and at least 34% formerly licensed THM had shifted to the less strictly regulated food sector, while up to 54% might have disappeared from the market. However, there is still a significant presence of retail websites making illegal health claims.

Conclusion: In Spain, the public health benefits of the Directive 2004/24/EC might be less than expected.

© 2014 SESPAS. Published by Elsevier España, S.L.U. All rights reserved.

Efecto en España de la directiva Europea de uso tradicional sobre el registro de medicamentos a base de plantas

R E S U M E N

Antecedentes: En 2011 entró totalmente en vigor la Directiva 2004/24/CE, que impone nuevos requerimientos a los medicamentos tradicionales a base de plantas. Este trabajo analiza el efecto sobre su registro en España.

Métodos: Se consultaron los catálogos de plantas medicinales y de medicamentos (CGCOF), la página web de la Agencia Europea del Medicamento (EMA) y sitios de venta en Internet.

Resultados: De los 315 medicamentos a base de plantas autorizados en 2010, procedentes de 39 compañías; solo quedaban 48 (10 compañías) en 2013 por renuncia de la mayoría: sólo 123 solicitudes fueron recibidas a la EMA y al menos un 34% se pasó al sector de alimentación (menos estrictamente regulado). Hasta un 54% podría no comercializarse actualmente. Sin embargo, existe una presencia significativa de sitios web anunciando ilegalmente propiedades saludables para sus productos.

Conclusión: Los beneficios de la Directiva 2004/24/CE para la salud pública española podrían ser menos de los esperados.

© 2014 SESPAS. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Ten years ago, the Directive 2004/24/EC (the Directive) established a regulatory framework for traditional herbal medicinal products. The Directive, which came fully into force in Spain on 1 May 2011, requires these products to meet specific and appropriate standards of efficacy, safety and quality to protect public health.¹

In order to simplify the nomenclature, we will use along this article the term “Traditional Medicines” (TM) to refer to both the old and the current licensing categories of traditional herbal medicinal products.

The Directive provides for a special simplified registration procedure for TM. But actually it creates significant new regulatory requirements because manufacturers have to prove that their products have been made to strict standards of safety and quality. The resulting new costs to manufacturers might result in loss of the commercial viability of individual TM so that there might be fewer TM on the market and a smaller range. This work compares the register of TM in Spain before and after the Directive came fully into force in 2011.
Results

Fig. 1 shows the evolution of the Spanish market of TM between 2005 and 2013. The number of licensed TM diminished from 424 in 2005 to 315 in 2010, while there was no change in the number of producing companies (39). But these numbers sharply dropped immediately after the Directive fully came into force, so that in 2011 there were only 38 granted TM (i.e. 12% out of 315 TM) and they were produced by just 7 companies. This was mainly due to the fact that the producing companies refused to apply for the required marketing authorisations, since ii) the EMA had only received 123 applications for traditional use registration from Spain by December 2013 and ii) at least 34% formerly licensed TM in 2010 (i.e. 108 out of 315 TM) was instead registered as food or food supplement in 2013 and up to 54% might have disappeared from the market (we were unable to determine their status).

Methods

We studied the effect of the Directive on the register of TM in Spain by comparing the number of TM licensed under either the former legislation (years 2005, 2006 and 2010) or the Directive (years 2011, 2012 and 2013). These data were obtained respectively from the catalogues of Medicinal Plants1-4 and Drug and Medicinal Products (Botplus version)5 published by the General Council of Official Colleges of Pharmacists. Two researchers (from NTG, CGP, ENA and JBE) extracted data independently from each annual catalogue. The extracted data were cross-checked by the authors, and any discrepancy was resolved by discussion with a third author (FJLC).

The data of 2011 and 2013 on Traditional Use Registrations from the European Medicines Agency (EMA)6,7 were analyzed by two researchers (CGP and JBE) in order to make an estimate of the number of former TM which refused to apply for a marketing authorisation under the Directive. In this connection, a further study was undertaken for making an estimate of their possible commercialization in the food market through i) searching in the catalogues of the General Council of Official Colleges of Pharmacists5, ii) enquiring to the manufacturing laboratories and iii) searching the Internet using Yahoo and Google search engines and entering the search term “comprar planta medicinal” (“to buy medicinal plant”). The Spanish retail sites found were analyzed for the commercialization of former TM.

Since we detected on the Internet illegal health claims, we conducted a second search aimed to make a preliminary evaluation of the magnitude of the problem. We entered “to buy herbal medicine”, both in English and Spanish and, from the first 500 consecutive retail sites found, we selected the ones whose products could be bought from Spain. Then, they were evaluated for illegal health indications.

The two searches on the Internet were conducted in 2013, from October to December, and each web site was analyzed independently by two authors (from NTG, CGP, ENA, JBE, AMM and FJLC). In case of conflicting reports on the evaluation of health or therapeutic claims, the final decision was taken by the whole author team.

Discussion

Our results clearly indicate that the simplified registration for TM is actually a very exigent procedure so that, only 12% formerly licensed TM in Spain had been granted a license in 2011 under the Directive. As regard the producing companies, they have also suffered the same “mass extinction” than TM upon the “Directive impact” on the Spanish market. Furthermore, at least 34% formerly licensed TM are now marketed as food or food supplements and we have been unable to confirm that more than a half of them are currently commercialized. By contrast, the implementation of the Directive in Germany resulted in the licensing of 45% former TM8.

Our data suggest that the Directive has triggered in Spain the massive shift of herbal medicines into the least strictly regulated food sector. We have not addressed the causes behind the strong effect of the Directive in the Spanish TM market. However, according to a survey, only one third (36.6%) of the Spanish consumers of herbal products used to treat health conditions buy them at pharmacies9. In other European Countries as Germany, this figure is almost inverse10. Therefore, if herbal products traditionally used to treat health conditions are mainly bought in shops for herbal products rather than in pharmacies, why should the producing companies apply for a much more expensive traditional use registration?

The shift of TM into the food sector in Spain may have important consequences as people determined to keep taking their favourite unlicenced herbal medicines may go online and choose to buy them from merchants who may be careless about quality or potency: in a recent review of 13 common herbals of the top 50 Web sites, only 10.5% recommended consultation with a healthcare professional and fewer than 8% of retail sites provided information regarding potential adverse effects, drug interactions, and other safety information11. Even worse: we have found more than 60 websites advertising herbal medicinal products under illegal therapeutic claims. Similar results were published recently in a report on food supplement brands traded over the Internet in Spain12. These facts somehow subvert the purpose of the Directive, which was aimed at ensuring protection for public health through well established standards of quality, safety and patient information.

In summary, the Directive has brought about a dramatic drop in the number of licensed TM in Spain in favour of their marketing in the food sector. The expected benefits of the Directive to the Spanish public health might be compromised, particularly by the Internet marketing of herbal products with illegal health claims.
What is already known about this subject?

The Directive 2004/24/E pursues, through the strict regulation of herbal medicinal products, a high level of consumer protection in the EU. However, it contains major burdens for applicants often connected with high monetary costs.

What does this paper add?

Almost 90% formerly licensed traditional herbal medicines are no longer licensed in Spain and there has been an important shift into the food sector. This means that they are no longer subject to the strict pre- and post-market control of the medicinal products, which clearly subverts the purpose of the Directive.

Editor responsible for the article

Carme Borrell.

Contributions of authorship

Noelia Tejedor-García and Francisco Javier de Lucio Cazaña conceived the study, participated in its design and collaborated collecting and interpreting the data. They have written the draft of the manuscript, especially: Introduction, Results and Discussion. Coral García-Pastor participated in the design of the study and in collecting and interpreting the data as well. She has helped to draft the manuscript and also has checked and discussed the article, especially the results. Javier Blas-Espada and Estefanía Navalmoral-Arenas have collaborated in the design of study methodology and in the collection and interpretation of the data. They have also checked and discussed the article, especially the results. Antonio Madrigal-Martínez collaborated in the collection and interpretation of the data, made the figure and participated in drafting of the manuscript. All authors read and approved the final manuscript.

Funding

This article has been funded by the research fund of the Departamento de Biología de Sistemas.

Conflicts of interest

There are no conflicts of interest to disclose.

Acknowledgements

The authors wish to thank the Spanish Consejo General de Colegios Oficiales de Farmacéuticos for its contribution to this article.

References